STAT3 Phosphorylation Inhibition for Treating Inflammation and New Bone Formation in Ankylosing Spondylitis. (2020)
https://pubmed.ncbi.nlm.nih.gov/33237331/

Switching to biosimilars in the treatment of rheumatic diseases (2018)
https://pubmed.ncbi.nlm.nih.gov/29914272/

Expression of activation-induced cytidine deaminase splicing variants in patients with ankylosing spondylitis (2017)
https://pubmed.ncbi.nlm.nih.gov/28959900/

Developing a Risk-scoring Model for Ankylosing Spondylitis Based on a Combination of HLA-B27, Single-nucleotide Polymorphism, and Copy Number Variant Markers. (2016)
https://pubmed.ncbi.nlm.nih.gov/27909141/

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. (2016)
https://pubmed.ncbi.nlm.nih.gov/27101309/

An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population (2015)
https://pubmed.ncbi.nlm.nih.gov/26613595/

ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients (2015)
https://pubmed.ncbi.nlm.nih.gov/25917849/

Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/25121767/

Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/24692264/

Restoration of overexpressed variable heavy chain 2 transcripts with tumor necrosis factor inhibitors in ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/24585525/

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci (2013)
https://pubmed.ncbi.nlm.nih.gov/23749187/